Background
Burfiralimab (hzVSF-v13) is a monoclonal IgG4 antibody against vimentin expressed on the surface of virus-infected cells, with broad-spectrum antiviral activity and anti-inflammatory effects against virus-induced inflammation. Burfiralimab can be used in severe COVID-19 studies.• Roles of vimentin in health and disease., PMID:35487686• Spatial single-cell protein landscape reveals vimentinhighmacrophages as immune-suppressive in the microenvironment of hepatocellular carcinoma., PMID:39327501• Atractylodinol prevents pulmonary fibrosis through inhibiting TGF-β receptor 1 recycling by stabilizing vimentin., PMID:37641404• FAM171B stabilizes vimentin and enhances CCL2-mediated TAM infiltration to promote bladder cancer progression., PMID:37915048• Vimentin Inhibits Dengue Virus Type 2 Invasion of the Blood-Brain Barrier., PMID:35433510• Vimentin on the move: new developments in cell migration., PMID:30505430• Vimentin, inversely correlating with infiltration of CD8 + T lymphocytes, promotes nuclear translocation of PD-L1 in esophageal squamous cell carcinoma., PMID:38901494• Vimentin as a universal receptor for pseudorabies virus infection in pig and human cells., PMID:39549807• PROTAC-mediated vimentin degradation promotes terminal erythroid differentiation of pluripotent stem cells., PMID:39294765• Vimentin, colon cancer progression and resistance to butyrate and other HDACis., PMID:27072512